Benzinga · Aug 12, 2026
Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $166
Canaccord Genuity analyst Whitney Ijem maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $180 to $166.
NG
NASDAQ · NGNE
Neurogene Inc.
Healthcare · Biotechnology
$36.58
Down-$0.69 (-1.89%)
Updated Aug 31, 2026, 3:20 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 329.3M
- P/E ratio
- -5.29
- Dividend yield
- 0.00%
- 52-week range
- $18.23 – $43.66
- Volume
- 132.8K
- Avg. volume
- 231.35K
Price performance
NGNE price history
1M range · 20 trading sessions · Daily adjusted prices
NGNE closed at $36.58 after 20 trading sessions, up 11.29% for the selected period.
- Last close
- $36.58
- Period change
- +11.29%
- Period low
- $32.87
- Period high
- $40.84
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $37.68 | $38.56 | $36.315 | $36.58 | 132.8K |
| Aug 27, 2026 | $38.50 | $39.81 | $37.39 | $37.86 | 149.92K |
| Aug 26, 2026 | $40.74 | $41.77 | $38.27 | $38.41 | 180.17K |
| Aug 25, 2026 | $40.09 | $42.01 | $39.125 | $40.84 | 504.34K |
| Aug 24, 2026 | $38.64 | $40.82 | $37.50 | $39.64 | 439.1K |
| Aug 21, 2026 | $38.41 | $39.44 | $37.535 | $38.63 | 346.58K |
| Aug 20, 2026 | $38.55 | $38.60 | $36.78 | $37.99 | 124.69K |
| Aug 19, 2026 | $36.85 | $40.155 | $35.90 | $39.43 | 383.1K |
| Aug 18, 2026 | $36.35 | $36.99 | $35.21 | $35.67 | 88.44K |
| Aug 17, 2026 | $36.14 | $37.18 | $35.42 | $36.68 | 91.13K |
| Aug 14, 2026 | $35.44 | $36.40 | $34.465 | $36.14 | 115.86K |
| Aug 13, 2026 | $37.24 | $38.00 | $35.47 | $35.63 | 140.29K |
| Aug 12, 2026 | $36.59 | $37.275 | $35.715 | $36.98 | 342.64K |
| Aug 11, 2026 | $36.19 | $36.27 | $30.57 | $35.80 | 352.61K |
| Aug 10, 2026 | $35.68 | $36.89 | $35.19 | $36.55 | 214.31K |
| Aug 7, 2026 | $36.02 | $36.68 | $34.60 | $35.69 | 103.22K |
| Aug 6, 2026 | $36.01 | $36.50 | $35.375 | $35.60 | 94.29K |
| Aug 5, 2026 | $34.66 | $36.30 | $34.36 | $35.98 | 167.58K |
| Aug 4, 2026 | $33.01 | $34.6199 | $33.01 | $34.41 | 142.21K |
| Aug 3, 2026 | $33.52 | $33.69 | $31.86 | $32.87 | 155.55K |
Latest NGNE news
The latest Smart Investors Daily articles mentioning NGNE.
Stock researchCompany · Overview
NGNE research
Overview
Company profile and research snapshot.
Company profile
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $45.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Canaccord Genuity | Buy | — |
| Aug 12, 2026 | Guggenheim | Buy | — |
| Aug 12, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 9, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 6, 2026 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 12, 2026
Guggenheim Maintains Buy on Neurogene, Raises Price Target to $81
Guggenheim analyst Debjit Chattopadhyay maintains Neurogene (NASDAQ:NGNE) with a Buy and raises the price target from $69 to $81.
Benzinga · Aug 12, 2026
HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $65
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $70 to $65.
Benzinga · Aug 11, 2026
Neurogene Q2 EPS $(1.53) Misses $(1.39) Estimate
Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.53) per share which missed the analyst consensus estimate of $(1.39) by 10.07 percent. This is a 45.71 percent decrease over losses of $(1.05) per share from the
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
